Recro Pharma Inc (NASDAQ:REPH) has been assigned a consensus rating of “Buy” from the eight brokerages that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $14.42.
A number of analysts recently commented on the company. Zacks Investment Research upgraded Recro Pharma from a “sell” rating to a “hold” rating in a report on Tuesday, October 31st. Piper Jaffray Companies reiterated a “buy” rating and set a $11.00 price target on shares of Recro Pharma in a report on Friday, October 27th. CIBC assumed coverage on Recro Pharma in a report on Wednesday. They set an “outperform” rating and a $19.00 price target on the stock. UBS Group assumed coverage on Recro Pharma in a report on Tuesday, February 13th. They set an “outperform” rating on the stock. Finally, Oppenheimer assumed coverage on Recro Pharma in a report on Tuesday, February 13th. They set an “outperform” rating and a $19.00 price target on the stock.
Shares of Recro Pharma (REPH) traded down $0.40 during trading on Tuesday, reaching $8.30. The company had a trading volume of 166,435 shares, compared to its average volume of 117,181. Recro Pharma has a 1-year low of $5.81 and a 1-year high of $10.59. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.35 and a current ratio of 1.59.
In other Recro Pharma news, major shareholder Scp Vitalife Partners (Israel) sold 12,964 shares of the firm’s stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $8.88, for a total value of $115,120.32. Following the completion of the sale, the insider now directly owns 734,269 shares of the company’s stock, valued at $6,520,308.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Scp Vitalife Partners Ii Lp sold 18,231 shares of the firm’s stock in a transaction on Friday, December 29th. The stock was sold at an average price of $9.27, for a total value of $169,001.37. The disclosure for this sale can be found here. Insiders sold 860,414 shares of company stock valued at $8,289,916 over the last three months. Company insiders own 21.60% of the company’s stock.
Large investors have recently added to or reduced their stakes in the business. Teachers Advisors LLC purchased a new stake in Recro Pharma in the second quarter worth $162,000. Two Sigma Investments LP purchased a new stake in Recro Pharma in the fourth quarter worth $164,000. California State Teachers Retirement System purchased a new position in shares of Recro Pharma in the second quarter valued at $169,000. JPMorgan Chase & Co. grew its position in shares of Recro Pharma by 183.4% in the third quarter. JPMorgan Chase & Co. now owns 21,784 shares of the specialty pharmaceutical company’s stock valued at $197,000 after purchasing an additional 14,098 shares in the last quarter. Finally, Strs Ohio grew its position in shares of Recro Pharma by 455.0% in the fourth quarter. Strs Ohio now owns 22,200 shares of the specialty pharmaceutical company’s stock valued at $205,000 after purchasing an additional 18,200 shares in the last quarter. 61.88% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This story was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/18/recro-pharma-inc-reph-receives-13-50-average-price-target-from-analysts.html.
Recro Pharma Company Profile
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.